tailieunhanh - Báo cáo sinh học: "Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation"

Tuyển tập các báo cáo nghiên cứu về sinh học được đăng trên tạp chí sinh học Journal of Biology đề tài: Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation | Genetic Vaccines and Therapy BioMed Central Short paper Open Access Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation Norma Perez1 Pascal Bigey2 Daniel Scherman2 Olivier Danos1 Marc Piechaczyk3 and Mireia Pelegrin 3 Address 1Généthon UMR 8115 CNRS 91002 Evry France 2Unité de Pharmacologie Chimique et Génétique FRE CNRS 2463 - INSERM U640 Faculté de Pharmacie Université René Descartes 75270 PARIS France and institute of Molecular Genetics of Montpellier UMR 5535 IFR122 CNRS 34293 Montpellier France Email Norma Perez - Pascal Bigey- Daniel Scherman - Olivier Danos - odanos@ Marc Piechaczyk - piechaczyk@ Mireia Pelegrin - pelegrin@ Corresponding author Published 23 March 2004 Received 23 December 2003 Accepted 23 March 2004 Genetic Vaccines and Therapy 2004 2 2 This article is available from http content 2 1 2 2004 Perez et al licensee BioMed Central Ltd. This is an Open Access article verbatim copying and redistribution of this article are permitted in all media for any purpose provided this notice is preserved along with the article s original URL. Abstract The clinical application of monoclonal antibodies mAbs potentially concerns a wide range of diseases including among others viral infections cancer and autoimmune diseases. Although intravenous infusion appears to be the simplest and most obvious mode of administration it is very often not applicable to long-term treatments because of the restrictive cost of mAbs certified for human use and the side effects associated with injection of massive doses of antibodies. Gene cell therapies designed for sustained and possibly regulatable in vivo production and systemic delivery of mAbs might permit to advantageously replace it. We have already shown that several such approaches allow month- to year-long ectopic antibody production by